Fresh off a major clinical win, Revolution Medicines alleges that Erasca’s pancreatic cancer drug infringes on key patent ...
Revolution Medicines’ stock has surged on the promise of a pancreatic-cancer drug. With any deal to buy the firm looking ...
Erasca shares fell after Revolution Medicines alleged that the company's development of its ERAS-0015 cancer treatment infringes on existing patents and relies on stolen trade secrets.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results